Rush Street Interactive Announces Second Quarter 2025 Earnings Release Date

(NYSE:RSI), CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) — Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”) today announced that it will release its second quarter 2025 results after the market close on Wednesday July 30, 2025, followed by a conference call at 6:00 pm Eastern Time (5:00 pm Central Time) to discuss the results. RSI's earnings […]

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

(NASDAQ:CELU),(NASDAQ:CELUW), Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain management. FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a

Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements

(NASDAQ:HSDT), NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

(TSX:SVA),(OTC US:SEOVF),(Other OTC:SEOVF),(XETRA:PSH.DE),(Frankfurt:PSH),(NASDAQ:ELDN), LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) — Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) to evaluate Eledon's immunosuppressive agent tegoprubart (AT-1501) in Sernova's ongoing Phase 1/2 clinical trial of its Cell Pouch Bio-hybrid Organ in patients

FST Corp. Announces Expansion of Fulfillment Center in Garden Grove, California

(NasdaqGM:KBSX), BOULDER, CO, July 09, 2025 (GLOBE NEWSWIRE) — FST Corp. (Nasdaq: KBSX), a leading manufacturer and marketer of steel and graphite golf shafts and a provider of other golf-related services, today announced it has approved plans to expand its fulfillment facility located in Garden Grove, California, adding an additional 5,424 square feet, or 155

TRIMEDX ranked 30th Inspiring Workplace in North America and recognized as Best in Class Leadership

Indianapolis, Indiana, July 09, 2025 (GLOBE NEWSWIRE) — TRIMEDX―a leading independent clinical asset management company delivering clinical engineering services, clinical asset informatics, and medical device cybersecurity― is proud to announce it has been ranked 30th on the 2025 list of Top 100 Inspiring Workplaces in North America by the Inspiring Workplaces Group. In addition, TRIMEDX

MDWerks’ Two Trees Beverage Subsidiary Receives Three 2025 SIP Awards

(Other OTC:MDWK),(OTC US:MDWK), GREEN COVE SPRINGS, Fla., July 09, 2025 (GLOBE NEWSWIRE) — MDWerks, Inc. (“MDWerks” or the “Company”) (OTCQB: MDWK), a forward-thinking company leading the charge in the world of sustainable technology, today announced that its subsidiary, Two Trees Beverage Company (“Two Trees”), received three 2025 SIP Awards, including a Silver Medal and an

Live Oak Bancshares, Inc. Announces Date of Second Quarter 2025 Financial Results

(NYSE:LOB), WILMINGTON, N.C., July 09, 2025 (GLOBE NEWSWIRE) — Live Oak Bancshares, Inc. (NYSE: LOB) today announced that it will report its second quarter 2025 financial results after U.S. financial markets close on Wednesday, July 23, 2025. In conjunction with this announcement, Live Oak will host a conference call to discuss the company's financial results

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

(NASDAQ:ADIL), GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of an update to the provisional patent application for AD04 which was filed in July

Stantec to release second quarter 2025 results on August 13, 2025 and host conference call on August 14, 2025

(TSX:STN),(NYSE:STN), EDMONTON, Alberta, July 09, 2025 (GLOBE NEWSWIRE) — TSX,NYSE: STN Stantec, a global leader in sustainable design and engineering, will release its second quarter 2025 financial results after markets close on Wednesday, August 13, 2025. On Thursday, August 14, 2025, at 7:00 AM Mountain Time (9:00 AM Eastern Time), Gord Johnston, president and chief

Scroll to Top